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1. Introduction 
Neovascularization is defined as formation of new vessels from vascular endothelial cells 
derived from existing blood vessels. These new immature vessels are friable. They have 
increased permeability, lack structural integrity, and can result in lipid deposition and 
corneal opacities. Ultrastructurally, corneal neovascularization is characterized by vessels 
encroaching through separated stromal lamellae. Corneal vascularization following 
penetrating keratoplasty may result in graft rejection. 
2. Pathophysiology 
Angiogenesis is a complex processs. First, inflammatory mediators trigger vasodilation and 
increase vascular permeability of limbal and conjunctival vasculature. Vascular endothelial 
growth factor (VEGF) is one of the most important regulators of corneal angiogenesis. It is 
produced primarily by macrophages, T cells, and smooth muscle cells in ocular surface. 
A second important regulator of corneal neovascularization is basic fibroblast growth factor 
(bFGF) and the third important signal is platelet aggregation factor (PAF). Others include 
insulin like growth factor, integrins, transforming growth factor, tumor necrosis factor and 
matrix metalloproteinase. 
Corneal neovascularization can be prevented by various anti angiogenic factors that have 
been identified in the cornea. Angiostatin, a proteolytic fragment of plasminogen prevents 
neovascularization and also induces regression of existing vessels. This has been identified 
in chronic contact lens user where it suppresses the angiogenic stimuli of hypoxia. Second 
antiangiogenic factor is endostatin which is a proteolytic fragment of collagen XVIII inhibits 
bFGF and VEGF stimulated corneal neovascularization. Third naturally occurring 
antiangiogenic factor is pigment epithelium derived growth factor (PEDF) which is a serine 
protease inhibitor and inhibits bFGF stimulated corneal neovascularization.  
Corneal neovascularization most frequently results from corneal oxygen deprivation, or 
hypoxia. In response to this hypoxia, the body attempts to provide necessary nutrients and 
oxygen to the deprived corneal tissues by the creation of new blood vessels. During the 
early stages, this abnormal growth of blood vessels may produce no signs at all, or it may 
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cause a variety of symptoms, including eye pain and excessive tearing, light sensitivity, 
redness, intolerance to contact lenses, and decreased vision. 
Role of Corneal Neovascularization in Corneal Graft Rejection 
Corneal neovascularization remains a significant risk factor for corneal graft rejection and 
subsequent graft failure after penetrating keratoplasty. The collaborative corneal 
transplantation study1 identified, in addition to several other factors, the extent of stromal 
vessels (quadrants) as a serious risk factor for corneal graft failure. During corneal 
neovascularization, an upregulation of angiogenic factors is seen in association with down 
regulation of antiangiogenic molecules. Studies in human and rat models have found 
vascular endothelial growth factor (VEGF) to be up regulated in inflamed and vascularized 
cornea .2 In a mouse model, it was observed that corneal avascularity during development is 
redundantly regulated. Lack of the antiangiogenic factors thrombospondin (TSP)-1 and/or -
2 resulted in no spontaneous corneal angiogenesis. By contrast, TSP-1, more than TSP-2, 
helped to suppress inflammation-induced corneal angiogenesis postnatally, implying that 
angiogenic privilege in the cornea is actively maintained .3 Bachmann et al4  in a mouse 
model found that neutralization of VEGF-A after high-risk corneal transplantation 
effectively inhibited postoperative hemangiogenesis, lymphangiogenesis, and recruitment 
of antigen-presenting cells, thereby improving corneal graft survival. 
Vascular endothelial growth factor  promotes several steps of angiogenesis, including 
proteolytic activities, endothelial cell proliferation, migration, and capillary tube formation . 
5 Topical or systemic application of bevacizumab inhibited both inflammation-induced 
angiogenesis and lymphangiogenesis in the cornea. This finding suggestes an important role 
of VEGF-A in corneal lymphangiogenesis and bevacizumab may be useful in preventing 
immune rejections after penetrating keratoplasty. 
3. Types of corneal vascularization 
Superficial: In superificial corneal vascularization, vessels arrange in arborizing pattern in 
subepithelial layer and can be traced with conjunctival vessels. This type of vascularization 
may be observed in trachoma, and phlyctenular conjunctivitis. 
Deep:  In deep corneal vascularization, vessels are derived from anterior ciliary artery and 
lie in corneal stroma. Vessels are usually straight and not anastomosing.  This type of 
vascularization may be observed in graft rejection, interstitial keratitis, deep corneal ulcer, 
and chemical burn. 
Pannus: In pannus, extensive superficial vascularization occurs with cellular infiltration. It 
is of two types: 
 Progressive:  Infiltration is ahead of vascularization 
 Regressive:  Infiltration is behind the vascular leash. 
4. Associated symptoms  
Symptoms of corneal neovascularization often include the following: 
 Eye pain 
 Redness 
 Tearing and photophobia 
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 Contact lens intolerance 
 Decreased vision 
4.1 Advantages of neovascularization 
 Transport humoral and cellular elements of immunological defence and raw material 
 Repair and regeneration 
 Carry antibiotic and drugs to site of infection 
 Eliminates toxic substances 
4.2 Disadvantages of neovascularization 
 Interfere with corneal transparency 
 Graft rejection and failure in keratoplasty 
 Sensitization to other antigen 
4.3 Complications 
 Corneal edema 
 Corneal opacity 
 Graft rejection in keratoplasty 
 Lipid keratopathy 
 Intrastromal/subepithelial bleeding 
 It can also lead to blindness 
5. Management 
Corneal neovascularization is one of the main risk factor for immune rejection after 
corneal transplantation. Healthy cornea is devoid of blood vessels and is said to be 
immune privileged. When corneal grafts are placed into an avascular recipient corneal 
bed (low risk keratoplasty) the two year survival rate approaches 90% under cover of 
steroids. 
The survival rates of corneal grafts placed over vascularized recipient beds (high risk 
keratoplasty) decrease significantly. Even in low risk setting, mild angiogenesis develops 
after keratoplasty and increase risk of immune graft rejection. For this reason aggressive 
treatment of neovascularization may be necessary prior to corneal transplant surgery to 
ensure lower risk of graft rejection. 
Various antiangiogenic agents may be used in management of post keratoplasty graft 
rejection:  
 Angiostatic steroids 
 Vascular endothelial growth factor inhibitor 
 Protein kinase c inhibitor 
 MMP inhibitor 
 COX-2 inhibitor 
 Antioxidants  
 Dietary derived inhibitor 
Corticosteroids and systemic immunosuppression remain an important aspect in prevention 
of post keratoplasty graft rejection. Corticosteroids inhibit macrophages that release growth 
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Fig. 1. Effect of topical bevacizumab in a case of corneal neovascularization. A. Pre-
treatment: Corneal vascularization and stromal haze is visible. B. Post-treatment: Marked 
regression in corneal vascularization and stromal haze has resulted. 
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factor. They also prevent intercellular adhesion leading to leukocyte adhesion and 
migration. They can slow the progression of neovascularization, but cannot stabilize or 
reverse the process. 
Vascular endothelial growth factor inhibitors are emerging as the new pharmacological 
therapy in the management of post keratoplasty graft rejection. Anti-VEGF agent has been 
found to be effective in reducing corneal vascularization (Fig. 1). Currently available anti-
VEGF agents include: 
 Bevacizumab (Avastin) Bevacizumab is a humanized monoclonal antibody that 
inhibits all active isoforms of VEGF and is approved by USFDA since February 2004 for 
treatment of metastatic colorectal cancer. 
 Ranibizumab (Lucentis) Ranibizumab is also a humanized monoclonal antibody 
fragment highly related to bevacizumab structurally. 
 Pegaptanib (Macugen) Pegaptanib is a synthetic oligonucleotide that binds the 
pathologic isoform of VEGF, which is VEGF 165 and this binding, happens 
extracellular. 
5.1 Role of bevacizumab in the treatment of corneal vascularization 
Efficacy of bevacizumab therapy has been highlighted in several studies. Manzano et al 6 in 
an experimental study on rats showed that a concentration of 4 mg/mL bevacizumab limits 
corneal neovascularization. Dastjerdi et al7  in their study used 1%  bevacizumab for 3 weeks 
in 10 eyes of 10 patients and followed them up to 24 weeks. They found that short-term 
topical bevacizumab therapy reduced the severity of corneal neovascularization without 
local or systemic adverse effects. Chen et al8 used subconjunctival injection of bevacizumab 
in doses 0.25-2.5 mg twice per week for 2 to 8 weeks in rabbits and concluded that it is 
effective in preventing corneal neovascularization in acute phase of various kinds of corneal 
inflammation. Carrasco 9 reported the use of bevacizumab in an 81-year old woman with 
corneal neovascularization secondary to herpetic stromal keratitis. Treatment with 
subconjunctival bevacizumab showed regression of corneal neovascularization. Bock et al10 
in their study used topical bevacizumab (5x/day; 5 mg/ml) for 15 days in corneal 
neovascularization of various cause and concluded that it inhibits corneal 
neovascularization without obvious corneal epithelial side effects. 
5.2 Role of bevacizumab in the treatment of corneal vascularization after keratoplasty 
Efficacy of bevacizumab therapy has been highlighted in several studies. Schollmayer et al11 
performed a retrospective case series study of nine eyes of nine patients with corneal 
transplant and neovascularization. Five eyes were administered topical bevacizumab 
5 mg/ml 4 times daily for a month. Three eyes were administered bevacizumab 
subconjunctivally 2.5 mg/0.1 ml and one eye was administered bevacizumab both topically 
as well via subconjunctival route. After a follow up of 6 months, it was concluded that 
topical and subconjunctival bevacizumab is effective in regressing neovascularization in 
keratoplasty patients. 
Saxena et al12 used topical bevacizumab (4 mg/4 ml) in dose of one drop twice daily for 15 
days in a patient of corneal graft rejection and did a follow up after 1 month, 6 month and 9 
months. After 1 month, his BCVA improved to 20/120 from finger counting 1meter. Corneal 














Fig. 2. Effect of topical bevacizumab on corneal neovasculariszation in a post-keratoplasty 
patient. A. Pre-treatment: Severe corneal vascularization and stromal haze is present. B. 
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with further regression in corneal vascularization and stromal haze resulted. At 9-month 
follow-up, he maintained BCVA of 20/60. Thus they concluded that short-term topical 
bevacizumab therapy may potentially offer a safer and more effective alternative in treating 
graft rejection after penetrating keratoplasty (Fig. 2). 
Despite effective results, corneal thinning and epithelial defect following topical 
bevacizumab instillation has also been reported.13 
6. Conclusion 
Although limited number of studies are available in literature, growing evidence suggests 
that bevacizumab offers a safe and effective mode of treatment for graft rejection following 
penetrating keratoplasty. 
7. References 
[1] Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and 
rejection in collaborative corneal transplantation studies: Collaborative Corneal 
Transplantation Studies Research Group. Ophthalmology. 1994; 101: 1536-1547. 
[2] Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and 
its receptors in inflamed and vascularised human corneas. Invest Ophthalmol Vis 
Sci. 2000;41: 2514-2522. 
[3] Cursiefen C, Masli S, Fong T, et al. Roles of thrombospondin- 1 and -2 in regulating 
corneal and iris angiogenesis. Invest Ophthalmol Vis Sci. 2004; 45: 1117-1124. 
[4] Bachmann BO, Bock F, Wiegand SJ, et al. Promotion of graft survival by vascular 
endothelial growth factor-A neutralization after high-risk corneal transplantation. 
Arch Ophthalmol. 2008; 126: 71-77. 
[5] Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularisation. 
Graefes Arch Clin Exp Ophthalmol 2007; 245: 1577-1579. 
[6] Manzano RPA, Peyman GA, Khan P, Petros E, Kivilcim CM, Ren M,  et al. Br J 
Ophthalmol. 2007;91:804-807. 
[7] Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda R 2nd, et al. 
Arch Ophthalmol. 2009;127:381-389. 
[8] Wei-Li Chen W , Chung-Tien Lin, Nien-Ting Lin,  et al. Bevacizumab on corneal 
neovascularisation in different rabbit models of corneal angiogenesis. Invest 
Ophthalmol Vis Sci 2010 51:6277-6285.  
[9] Carrasco MA.  Subconjunctival bevacizumab for corneal neovascularization in herpetic 
stromal keratitis Cornea. 2008;27: 743-745. 
[10] Bock F, König Y, Kruse F, Baier M, Cursiefen C.  Bevacizumab eyedrops inhibit 
corneal neovascularization. Graefe's Arch Clin Exp Ophthalmol. 2008; 246: 281-
284. 
[11] Schollmayer P, Stunf S, Lavric A. Pfeifer V. Topical and subconjunctival bevacizumab in 
corneal neovascularization in keratoplasty patients. Acta Ophthalmologica, 
2008;86: 0. doi: 10.1111/j.1755-3768.2008.570.x 
www.intechopen.com
 
Keratoplasties – Surgical Techniques and Complications 134 
[12] Saxena S, Kishore P, Pandey S, Khattri M, Kumar D. Topical bevacizumab for corneal 
neovascularization after penetrating keratoplasty.Eur J Ophthalmol. 2009;19:870-
872. 
[13] Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI. The effect of topical bevacizumab on corneal 
neovascularisation. Ophthalmology. 2008;115:E33-8. 
www.intechopen.com
Keratoplasties - Surgical techniques and complications
Edited by Dr. Luigi Mosca
ISBN 978-953-307-809-0
Hard cover, 134 pages
Publisher InTech
Published online 18, January, 2012
Published in print edition January, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
In this book, the authors illustrate different therapeutic and surgical approaches to treating various corneal
pathologies. This edition in electronic format allows universal access to everybody regardless of the time of
day or setting, portability, and speed of information access. Such features show more feasibility for all readers
and reduce the time necessary for research. This book will be a good tool for students as well as specialists
working in the field of corneal transplantation, to improve their knowledge of treatment of corneal disease.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Sandeep Saxena and Neha Sinha (2012). Topical Bevacizumab Therapy in Graft Rejection After Penetrating
Keratoplasty, Keratoplasties - Surgical techniques and complications, Dr. Luigi Mosca (Ed.), ISBN: 978-953-
307-809-0, InTech, Available from: http://www.intechopen.com/books/keratoplasties-surgical-techniques-and-
complications/topical-bevacizumab-therapy-in-graft-rejection-after-penetrating-keratoplasty
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
